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Effects of treatment with leptin-like peptides on factors related
to body fat control in Wistar rats fed a high-fat diet*
ELPIDIA POVEDA, MSC1, FRANCISCO RUIZ, ESP2, MARÍA CARLINA CASTILLO, ESP2
SUMMARY
Introduction: The results of administering recombinant leptin, as well as the 116-130 peptide of mouse leptin in ob/ob
mice have shown the probability of discovering more efficient leptin-based therapeutic methods to treat obesity.
Objective: To demonstrate in Wistar rats fed with high-fat diet if the administration of synthetic peptides corresponding
to the 116-130 peptide of mouse leptin (SR 116), its human homologue peptide (SH 95: sequence 95-109 from the 1AX8
protein) and five modified peptides (P80 to P84) similar to these two peptides, produces effects related to regulation of body
fat.
Materials and methods: Nine-week old Wistar rats were fed a high-fat diet for fifteen weeks. On the fifteenth week, and
for five consecutive days, they were treated with the peptides to be evaluated. During the days of treatment, body weight and
food intake were evaluated. After the last peptide administration, lipid profile, glycerol in the cellular medium, and DNA
fragmentation in adipocytes were analyzed.
Results: The results revealed that: the SR116 peptide affects the regulation of adiposity in rats fed a high-fat diet. The SH
95 is the human peptide with biological activity similar to SR 116 to lower weight, lessen food intake, and increase free
glycerol in the cellular medium. The P80 and P81 peptides had a similar effect on SR 116 and SH 95 regarding body weight
and food intake. The SR 116, SH 95 and three of the modified peptides (P80, P81, and P82) caused DNA fragmentation.
Conclusion: The results suggest that peptides analogous to leptin are potentially viable to achieve effects of adiposity
reduction in Wistar rats with obesity associated to high-fat diet; more research is rendered to explain the differences among
peptides and the biological action mechanisms.
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 Colomb Med. 2011; 42: 61-71
Efectos del tratamiento con péptidos similares a leptina sobre factores asociados con el  control de grasa corporal en
ratas Wistar alimentadas con dieta alta en grasa
RESUMEN
Introducción: Los resultados de administrar leptina recombinante así como del péptido 116-130 de leptina de ratón en
ratones ob/ob han demostrado la probabilidad de descubrir métodos terapéuticos más eficientes basados en leptina para tratar
la obesidad.
 Objetivo: Comprobar, en ratas Wistar alimentadas con dieta alta en grasa, si la administración de los péptidos sintéticos
correspondientes al péptido 116-130 de leptina de ratón (SR 116), péptido humano similar al de ratón (SH 95), correspon-
diente a la secuencia 95-109 de la proteína 1AX8 y cinco péptidos modificados (P80 a P84), similares a estos dos péptidos
produce efectos relacionados con la regulación de la grasa corporal.
Materiales y métodos: Ratas de 9 semanas de edad recibieron, durante 15 semanas, una dieta alta en grasa. En la semana
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15, por 5 días consecutivos, se trataron con los péptidos a
evaluar. Durante los días de tratamiento se evaluó el peso
corporal y el consumo de alimento. Después de la última
administración de los péptidos se analizó perfil lipidio,
glicerol en el medio celular y fragmentación del ADN en
adipocitos.
Resultados: Los resultados muestran que el péptido
SR116 ejerce efectos sobre el control de la adiposidad en
ratas alimentadas con dieta alta en grasa. El SH 95 es el
péptido  humano con actividad biológica similar al SR 116
para reducir peso, consumo de alimento y mayor liberación
de glicerol en el medio celular. Los péptidos P80 y P81
produjeron un efecto similar al SR 116 y al SH 95 en cuanto
a peso corporal y consumo de alimento. El SR 116, SH 95 y
tres de los péptidos modificados (P80, P81 y P82) ocasiona-
ron fragmentación del ADN.
Conclusión: Los resultados indican que péptidos análo-
gos a la leptina son potencialmente viables para lograr
efectos de reducción de la adiposidad en ratas Wistar con
obesidad asociada con dietas altas en grasa. Se requieren
otras investigaciones para explicar las diferencias entre
péptidos y los mecanismos de acción biológica.
Palabras clave: Grasas en la dieta; Adiposidad;
Análogos de leptina;  Terapéutica; Ratas Wistar.
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Leptin is a protein mainly synthesized in the
adipocytes, conformed in the mature state by 146 amino
acids. Its principal function is related to regulation of
fat deposits through endocrine, autocrine, and paracrine
actions that modulate appetite and regulate lipid
metabolism by increasing lipolysis and oxidation of
fatty acids, and inhibiting triglyceride synthesis within
the adipocyte1-4.
It has been noted that in mice with mutations in the
leptin gene (ob/ob mice) obesity and hyperglycemia are
associated to the lack of endogenous leptin. In obese
humans and obese rats, on the contrary, there are high
concentrations of plasma leptin, concomitant with
hyperphagia, hyperglycemia, and other metabolic
sequelae characteristic of obesity, suggesting a condition
resistant to leptin5-9.
The function of leptin in body fat regulation and in
the pathological alterations observed when the protein
is absent or when it is increased excessively led to
considering it a potential alternative for the treatment of
obesity and its co-morbidities. Initially, we tested the
administration of recombinant leptin, finding some
effects in decreasing body weight, diminishing
insulinemia, apoptosis in adipocytes, and reduction of
total cholesterol plasma concentrations, phospholipids,
free fatty acids, triglycerides, LDL cholesterol (LDLc),
and VLDL cholesterol (VLDL-c), as well as increased
concentrations of HDL cholesterol (HDLc)10-14.
It has been observed that in animal models, the
administration of recombinant leptin results more favo-
rable in controlling adiposity when administered in
intracerebroventricular (ICV)13 manner, which indicates
that it would not be a viable therapeutic method for use
in human subjects. Studies where recombinant leptin
has been administered in humans reveal inconclusive
results10. For this reason the possibility was considered
of using synthetic peptides that would conserve the
primary structure of the active segment. Initially, Grasso
et al.5, and Rozhavskaya et al.6 tested the synthetic
peptide corresponding to the mouse 116-130 leptin
segment in ob/ob mice, managing to reduce body weight,
appetite, and glucose. They then tested with the peptide
corresponding to the mouse 116-122 leptin sequence,
but substituting the amino acid from the 119 position
for its D-isomer D ([D-Leu-4]-OB3, finding a greater
reduction of body weight, appetite, and glucose5-7.
The experiments by Grasso et al.5 reveal that peptides
of between seven and 15 amino acids of the active
sequence are able to reproduce the activity of the native
protein and, additionally, indicate that the activity
depends upon the conformation of the peptide5-7. The
use of small peptides active in humans would reduce the
immunological risks of administering complete proteins.
From these considerations, the objectives of this research
were:
1. To prove if the synthetic peptide corresponding to
the mouse 116-130 leptin sequence (SR116) obtained
by Grasso could produce similar effects in an animal
model of Wistar rats with obesity associated to a
high-fat dietary intake.
2. To prove if the human peptide (SH 95), previously
postulated15,16 by our research group as homologous
to the mouse 116-130 leptin (sequence 95-109 of the
human leptin identified in the Protein Data Bank
(PDB) as 1AX8)15,16 has the potential to carry out
the same biological functions of murine regarding
weight control and control of food intake in the rat
model.
3. To determine other effects of SR 116 and SH 95 on
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the lipid profile, liberation of glycerol in the cellular
medium of adipose cells and fragmentation of
adipocyte DNA.
4. To assess if five peptides constructed from compu-
tational studies of sequence similarity and minimum
potential energy related with SR 116 and SH 9515,16
produce these same biological effects.
METHODS
Peptides. The conditions to carry out peptide
synthesis and the sequences were previously published16
and correspond to the following peptides:
1. SR 116: SCSLPQTSGLQKPES






Animals and experimental design. The description
of the animal model used in this study was detailed in
a prior publication16. This is hereinafter summarized in
general manner:
An animal model was used with 180 female Wistar
rats, nine weeks of age, supplied by the Colombian
Instituto Nacional de Salud (INS for its name in Spanish).
Upon starting the experiment, the animals were divided
into a control group fed a normal diet (is a low-fat diet
with 10 % kcal on fat but we denominated as normal
diet or normal control), a control group fed a high-fat
diet, and an experimental group fed a high-fat diet. All
the groups received the corresponding diet for a 15-
week period.
The selection of a 15-week period is substantiated
by prior studies that have shown that after 12 weeks of
feeding with these types of high-fat diets, the rats
manage to get significantly heavier than those fed
normal diets17. Likewise, it was decided on a period of
time not over 15 weeks because the evidence reveals
that as the animals become older there is greater
possibility of a state of leptin resistance associated to
aging. Our particular interest was to achieve increased
leptin concentrations related to diet in young adult
animals16,17.
On the 15th week, the experimental group was divided
into seven groups according to the peptide that would
be administered and each of the seven groups was also
divided into four subgroups according to the dosage
administered16 (dosage of 2.5 mg/kg; 5 mg/kg, 10 mg/
kg, and 20 mg/kg).
The peptides were administered intraperitoneally
(IP) for five consecutive days, bearing in mind some
studies where recombinant leptin was administered for
the same period18. The volume established was always
injected in the lower right abdominal region of the
animals. The control groups received 1 mg/kg of weight/
day of PBS solution via IP during these same five days.
In vivo determinations. During peptide adminis-
tration, changes in body weight and food intake were
evaluated. Twenty-four hours after the last peptide
administration blood was extracted via intra-cardiac
manner to determine blood concentrations of total
cholesterol (TChol), triglycerides (TG), LDLc and
HDLc. Immediately after collecting the blood, we
proceeded to dissect and extract adipose tissue from the
region where the peptides were administered to then
study the possible effects related to glycerol liberation
in the cellular medium of adipose cells and DNA
fragmentation in adipocytes17.
Serum lipid concentration. Serum lipid concen-
trations were determined with Serapak-Bayer reagents.
TChol and TGs were quantified via enzymatic methods
-colorimetry and HDLc were measured from the
supernatant after LDLc precipitation with phospho-
tungstic acid and magnesium ions. LDLc concentrations
were calculated through the difference between the
TChol concentration and the total cholesterol present in
the supernatant, which corresponds to VLDL cholesterol
and to HDLc.
Evaluation of glycerol liberated in the cellular
medium of adipocytes. We examined concentrations of
glycerol liberated in the cellular medium after subjecting
the intraperitoneal target adipose tissue from the zone
where peptide was administered to a process of digestion,
filtration, and separation. The procedure to determine
glycerol is an adaptation of the methodologies described
in different publications2,4,19:
One gram (1 g) of adipose tissue was taken from the
region where the peptides were administered. Then, the
tissue was subjected to digestion with collagenase
through agitation for 90 minutes at 37ºC; the process
was carried out in 50 ml polypropylene tubes. After the
digestion period, the resulting cell suspension was
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filtered through a nylon 100 µm mesh (steriflip filter
unit Millipore type NY1H), Krebs-Ringer bicarbonate
(KRB) was added and centrifuged for one minute at 400
rpm to eliminate the stromal vascular fraction. Again,
a fraction of the supernatant was taken, and KRB was
added again and it was centrifuged another time; this
procedure was repeated one more time, for a total of
three washing sessions and replacement of the medium.
Then, part of the supernatant was taken and incubated
at 37ºC for 90 minutes in 50 ml polypropylene tubes.
Thereafter, 1000 µl of the intermediate fraction was
centrifuged at 10000 rpm for one minute. Then, the
intermediate fraction of the adipocyte-free supernatant
was transferred to reaction tubes and stored at -70ºC,
until the moment of glycerol quantification.
The digestion solution contained a Krebs-Ringer
bicarbonate buffer solution (product N° K4002 from
Sigma with sodium bicarbonate); bovine serum albumin
V fraction, 3.5 g/100 ml (Sigma A3294 product); glucose
(1 mM), and collagenase type II (Sigma product N°
C6885). Per gram of fat tissue the proportion of digestion
solution was 5 ml and 6.7 mg of collagenase. The
solution presented pH of 7.4. To determine the concen-
tration of free glycerol in the medium, 10 µl were taken
from the supernatant. An enzymatic-colorimetric
method was used with SERAPK BAYER reagents of
triglyceride quantification (Sera-Pak Plus triglyceride
stable liquid N° B01-4512-01). The Merck Mega auto-
analyzer technique was used as quantification
equipment.
Evaluation of DNA fragmentation in adipose tissue.
We studied the possible fragmentation of deoxyribo-
nucleic acid (DNA) in target adipose tissue from the
region where the peptide or the phosphate buffer solution
(PBS) were administered. The procedure was divided
into two phases: the first was isolation of DNA from the
target adipose tissue and the second was electrophoresis
in polyacrylamide gel to observe the DNA bands; the
method was the following:
DNA isolation from intraperitoneal target adipose
tissue. The protocol to isolate DNA from adipose tissue
was adapted from the methodology described by
Gullicksen PS20 and the protocol for DNA detection
from the genomic DNA purification kit from Wizard
(isolation of genomic DNA from animal tissue p.10,
Promega A1120).
One milliliter of the buffer solution was added to
250 mg of adipose tissue for lysis (10 mM Tris-HCL, 10
mM of EDTA, 0.5% of Triton X-100, pH 8.0), then
macerated and homogenized. When the tissue was
macerated, it was transferred to a reaction tube, incubated
in ice for 20 minutes, and then centrifuged for 5 minutes
at 13,000 rpm and at 4ºC. The pellet (residue) remaining
at the bottom of the tube corresponds to insoluble DNA
and the supernatant to the soluble DNA. The fat cake
observed on the supernatant was discarded and soluble
DNA was separated from insoluble DNA.
Both insoluble DNA and soluble DNA received 600
µl of lysis solution for nucleic acids from the Promega
Wizard kit, and were incubated at 56ºC with agitation
for one hour. Each of the tubes received 3 µl of the
RNAase solution from Wizard and these were mixed by
inversion. They were left for 15 minutes at 37ºC and
then cooled to room temperature for five minutes or in
ice for 2 minutes.
Some 200 µl of the protein precipitating solution
were added and mixed in vigorous vortex for 15 seconds.
When the amount of soluble or insoluble DNA was
greater than 1.5 ml, half was transferred to another
reaction tube and 100 µl of the precipitating solution
was added to each tube. The tubes were left in ice for
five minutes and were centrifuged at 13,000 rpm for
five minutes.
The supernatant of insoluble DNA and soluble DNA
was again transferred to other reaction tubes; 600 µl of
absolute ethanol were added, the solution was mixed by
inversion to observe the DNA strands. It was centrifuged
for 1-2 minutes between 13,000 and 16,000 rpm at room
temperature and the supernatant was decanted.
The tubes were left to dry for 15 minutes. Then, 100
µl of tris-HCL and EDTA (TE) were added to the
insoluble DNA, and if there two tubes 50 µl were added
to each tube. A total of 30 µl of TE were added to the
soluble DNA or 15 µl per tube if there were two tubes.
DNA Electrophoresis of target adipose tissue from
the peritoneal region. Electrophoresis was performed
on the soluble and insoluble DNA fractions in
polyacrylamide gel at 6%. The gel was prepared at 6%
(distilled water: 28 ml, tris-borate (TBE) 10X: 4 ml,
30% acrylamide stock: 8 ml, ammonium persulfate at
10%: 240 µl and N, N, N’,N’-tetramethylethele-
nediamine (TEMED): 24 µl and left to polymerize for
one hour. Plate size was 17x14 cm with a capacity for
16 samples.
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As marker, we used 100 bp DNA Ladder (Promega
catalogue N° G2101), 2 µl per gel. We seeded 30 µl of
the simple with 5 µl of load buffer and electrophoresis
was run at a voltage of 1P80V for two hours. TBE 1X
was used as buffer; ethidium bromide was used as
colorant for 15 minutes and in cases requiring better
band resolution an additional SYBR Green I nucleic
Acid Gel Stain (from molecular probes) was used as
colorant for 45 minutes. For 400 ml of distilled water
we added 20 µl of ethidium bromide and for 400 ml of
TBE 10X 40 µl of SYBR Green.
DNA was visualized in a UV transilluminator and
photographs of the gel were taken with a black and
white Polaroid 667 film.
Statistical analysis. Data bases to manage data were
created in Excel and the statistical analysis was carried
out with the SPSS program, version 15 for Windows.
The variables studied were described by groups, using
the mean and standard deviation. To test differences
among groups in the study variables analysis of variance
(ANOVA) was applied and in cases in which this test
determined statistically significant differences post-
hoc comparisons were made through the Duncan test.
Analyses were worked at a confidence level of 95%
(p<0.05). DNA fragmentation results only indicate the
groups in which there was fragmentation.
Assessment of peptide effect upon body weight was
complemented through the calculation of the slope for
each weight curve corresponding to the period of peptide
administration.
Ethical considerations. Tests were conducted
according to scientific, technical, and administrative
guidelines for health research (Resolution N° 8430 of
1993), Legislation 84 of 1989 «Through which is adopted
the National Statute for Animal Protection», and the
ethical principles of animal experimentation from the
International Council for Laboratory Animal Science.
The study was approved by the Ethics Committee at the
INS.
RESULTS
Change of weight during the administration of the
peptides. In order to establish if the peptides administered
during the five days of treatment would produce some
variation in animal weight, we compared the weight
prior to administering the peptides (or the weight before
administering PBS for the control groups) with the
weight at the end of the test (comparison before and
after administration). The comparison revealed that
there was a weight decrease in all the experimental
groups, with the exception of P84 (Table 1). Weight
loss ranged between -0.2% and -2.4% (-0.6 g and -7.1
g). The normal control group increased and the fat
control group lost weight slightly without the differences
being statistically significant (Table 1).
The prior analysis was based on the weight
differences at the beginning and end of the peptide
administration period. However, it is possible to follow
the effect along the five days by determining the slope
of the curve of the weight decrease for each group.
Table 2 shows the tendency for body weight reduction
in the experimental groups, especially in the SR116,
SH95, and P80 to P81 peptides.
To determine if the effect of the peptides on weight
change was statistically different, we used the ANOVA
and Duncan tests. We tested to see if there were
differences among peptide groups (ANOVA:
p<0.00009): groups SR116, SH95, P80, and P81
presented weight reduction similar among them and
greater than the change observed in groups P82, P83,
and P84; nevertheless, the differences were statistically
significant among groups P78 to P81 and the normal
control and P84 groups. The weight change in group
P84 was not differentiated from the change observed in
the two controls or in groups 82 and 83 (Table 2).
When comparing the slopes according to the peptides,
differences were found among the groups (ANOVA
p<0.00009), identifying two groups in relationship to
the effect observed: the first, conformed by groups SR
116, SH95, P80, and P81, which show the most negative
slopes and without differences among them, while the
group conformed by P82, P83, P84, and fat control
show insignificant negative slopes. Weight reduction
by SR116 and SH95 was statistically significant with
respect to the weight change of the controls and from
the P82 to P84 peptides (Table 2).
The subgroups from each of the experimental groups
receiving peptide dosages of 2.5, 5, 10, and 20 mg/kg of
weight did not show statistically significant differences
among them, nor was any type of dosage effect response
noted (ANOVA p>0.05).
Food intake during peptide administration. To
establish the effect of peptides on food intake, we
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compared the food consumed during the five days
prior to peptide administration with consumption
during the five days of peptide administration. The
comparison revealed that the experimental groups
diminished their food intake between -12.4±52.3
and -48.0±38.6 kilocalories. The reduction in food
intake was statistically significant for each of the
groups, except P83 (Table 3). The fat control group
presented decreased food intake but it was not
significant (Table 3).
The analysis to establish differences among
groups proved that experimental groups P78 to P81
and P82 and P84 consumed similar amounts of
food amongst them and lower amounts than the fat
control group. The P83 group was only statistically
different from P84 (ANOVA: p=0.038) (Table 3).
Analysis of food consumption data during the
treatment days shows periods of greater and lower
food consumption and not a continuous decrease,
as noted with body weight. Table 4 shows that
groups SR 116 and SH 95 tended to consume the
same amount of calories during the five days. For
the P81 and P82 groups, food intake diminished
significantly during days 3 and 4, while for the P84
group there was a drastic reduction (10 kcal/day)
during the first two days followed by a four-fold
increase (40 kcal/day) to diminish to 20 kcal on the
last day. For the P83 group, there were no significant
daily differences in consumption (Table 4).
Intra-group comparison according to the
dosage of administration of each peptide did not
confirm significant differences (Anova p>0.05).
Blood lipid concentrations. Results of blood
lipid determination after the last peptide
administration are shown in Table 5.
Data show differences among peptide groups
and controls in concentrations of TChol HDLc,
LDLc, and TG. These differences evidence that in
all the experimental groups there was an increase
in TChol and LDLc with respect to the normal
control (ANOVA in Table 5). This effect could be
due to the high-fat diet, given that the fat control
also presented significantly greater concentrations
than the normal control. HDLc is similar in all the
groups and TGs in P80 and P81 show higher
concentrations than that of the control and experi-
mental groups (ANOVA in Table 5).
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Table 2
Average weight of the control groups and the experimental groups during the period
of peptide administration. Value of the slope of each curve
Group  Initial weight                           Weight on day                                     Final            Curve
        (g)               2 (g)      3 (g)      4 (g)      5 (g)    weight (g)        slope
                         X     DS               X     DS         X     DS        X     DS        X     DS          X      DS         X     DS
Normal
control 261.9±14.8 262.0±15.3 262.7±17.0 261.8±15.6 262.8±15.7 263.9±17.5 0.3229±0.6
Fat
control 291.6±19.7 289.4±21.3 289.9±20.0 290.4±19.9 288.5±19.0 288.5±19.9 -0.5024±1.4
SR116 293.6±23.3 290.6±24.0 290.0±23.6 289.0±23.6 286.7±23.6 286.5±23.4 -1.3816±0.8
SH95 294.6±24.0 291.7±24.6 290.6±24.7 288.3±24.3 286.6±24.0 287.9±23.9 -1.4439±0.8
P80 308.9±42.3 307.0±43.6 303.9±42.0 304.0±41.3 303.7±40.5 302.5±39.9 -1.2389±1.3
P81 306.4±30.8 304.1±31.0 301.8±30.4 301.4±29.9 300.8±30.5 299.9±30.0 -1.2204±1.3
P82 281.2±30.3 280.6±31.0 279.7±30.4 279.8±29.6 279.2±29.5 278.0±30.0 -0.5656±1.1
P83 279.6±13.0 277.9±13.5 278.4±13.4 279.3±13.2 279.6±12.3 276.7±13.0 -0.2448±0.7
P84 286.9±25.0 286.9±24.9 286.7±24.6 285.7±24.1 285.7±24.7 286.3±25.7 -0.216±0.9
Table 3
Mean food intake in kilocalories according to days of peptide treatment
Group           N                  Mean food intake in kcal
                                                   during the 5 days
                                   prior to peptide
                                 administration
    of peptide
    administration
           X     DS
        Difference of kcal       p value T test between
                intake                       related samples1
                                      X     DS X     DS
SR 116 24  169.0 ± 33.1 145.8 ± 33.1  -23.1 ± 37.3  p<0.0062
SH 95 24 166.4 ± 35.1  142.4 ± 29.4 -24.0 ± 37.3  p<0.006
P80 22 196.2 ± 34.1 153.7 ± 31.1 -42.5 ±-43.8 p<0.00009
P81 22 197.3 ± 30.5 152.5 ± 41.6 -44.8 ± 47.4 p<0.00009
P82 16 218.1 ± 27.4 173.8 ± 31.2 -44.4 ± 28.9 p<0.00009
P83 15 217.4 ± 24.3 205.0 ± 42.0 -12.4 ± 52.3  p=0.3
P84 19 167.9±23.1 119.9 ± 29.6 -48.0 ± 38.6 p<0.00009
Fat control 7 169.0 ± 22.9 159.0 ± 31.5 -10.0 ±38.9 p=0.3
1. p=0.01     2. Nonparametric test two samples
It can also be observed that a) treatment with SH 95
and P80 seems to diminish the effect of the diet on
TChol and LDLc; although, without significant
differences. b) Treatment with P82 and P84 increases
the effect of the diet on TChol and LDLc, but without
statistical significance (Table 5).
Concentrations of glycerol liberated in the
medium and DNA fragmentation. Table 5 shows
concentrations of glycerol liberated on the medium in
the control and experimental groups. The groups in
which the greatest concentration of glycerol was
liberated were the SH 95 and SR 116 groups. The
glycerol concentration for the SH95 group was similar
to the amount of glycerol liberated by the SR 116 group
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and apparently greater than that of the control groups
and the other experimental groups (ANOVA p=0.001).
No significant differences were found when comparing
the amount of glycerol liberated according to the dosage
administered of each of the peptides (ANOVA p>0.05).
DNA fragmentation was noted in groups P80, P81,
SH 95, SR 116, and P82; the effect was partial in all the
groups because it was present in some of the animals
that made up each experimental group (Table 6). The
divergence in the number of cases with fragmentation
hindered the possibility of confirming if the frag-
mentation percentages perceived in the groups were
statistically different from the control group. In spite of
this, a tendency for greater effect was noted with P80
and SH 95 peptides. The mean percentage of frag-
mentation was 2.8%±1.3, the minimum value was 1.4%
and the maximum value was 6.6%.
DISCUSSION
Evaluation of body weight during the period of
peptide administration revealed that all the experimen-
tal animals except for those in P84, experienced some
weight reduction caused by the peptides administered.
These results coincide with previous studies6-8 and
evidence, at the same time, the potential of the peptides
in treating obesity due to consumption of high-fat diets.
The results observed in this study also support the
hypothesis proposed by other authors in that peptides
similar to leptin can have a potential application in
human or veterinary medicine to control adiposity and
the metabolic sequelae associated with obesity21.
The results show that, in spite of the fact that all the
Table 5
Mean concentration of blood lipids according to groups conformed as controls and
experimental groups. Mean concentrations of glycerol freedom in the medium cell
                                                                                Mean (mg/dl)
Group             N                CT           HDLc                LDLc            TG              Glycerol
                            X    DS          X    DS             X    DS          X    DS    N     X    DS
SR 116 21 95.9±29.4 43.8±11.9 35.9±30.4 81.0±34.9 22 9.4 ±10.3*
SH 95 22 88.7±23.2 43.7±11.4 27.4±19.4 88.0±48.3 23 12.6±12.2*
P80 24 85.4±16.1 37.3±14.9 23.3±17.8 124.1±43.8 24  5.8±6.5
P81 23 98.2±37.4 37.9±15.0 38.6±37.3 129.3±53.4 23  4.7±2.4
P82 16 116.7±41.0 50.7±13.2 48.1±37.6 89.9±32.7  15  6.1±1.4
P83 15 92.0±25.7 54.7±12.0 22.0±22.3 75.9±25.9  15  6.2±1.2
P84 19 110.8±38.0 45.4±17.2 52.3±29.5 71.8±20.1  19  4.1±1.0
Normal control 6 77.0±15.9 38.9±22.3 11.7±8.6 92.3±6.7  5  6.2±2.2
Control graso 7 104.9±49.2 47.5±16.0 40.0±41.2 87.9±32.7 7  4.1±1.9
ANOVA* p=0.02 p=0.005 p=0.012 p<0.00009
*  Indicates if differences do exist
Table 4
Mean food intake in kilocalories according to
days of peptide treatment
Group                       Calories
                         2 days       2 days          1 day
   (day 1-3)      (day 4-5)  (day 5-6 post-
   treatment)
X    DS X    DS X    DS
Fat control 40.7±29.7 83.6±25.3 34.7±18.0
SR 116 62.4±16.2 50.5±18.3 32.9±12.4
SH 95 55.9±18.7 52.5±25.5 34.0±12.9
P80 81.5±25.3 21.6±12.3 50.5±18.8
P81 72.4±31.5 25.3±18.9 54.8±27.7
P82 56.5±31.9 72.8±14.6 44.5±16.6
P83 71.2±30.7 84.7±16.0 40.1±15.4
P84 19.3±14.5 80.2±32.3 20.4±9.4
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Table 6
Treatment groups in which DNA fragmentation was observed in adipose tissue
Group according
    to peptide
   Number of cases
 with fragmentation
Group according
    to peptide




peptide     concentration
     %  Mean DS   %  Mean DS
SR 116 1 SR 116-5.0 1  3  -  3 -
SH 95-2.5 1  - 2.9±2.5  6.6 -
SH 95 4 SH 95-5.0 2  -  1.4± 0.2
SH 95-20.0 1  2.1 -
P 80-2.5 5  - 2.9±1.1  -  2.4±0.8
P80 19 P 80-5.0 5  -  3.3±1.3
P 80-10.0 5  -  3.5±0.9
P 80-20.0 4  -  1.8±0.4
P81 5 P 81-5.0 5  - 2.0±0.5  -  2.0±0.5
P82 1 P 82-10.0 1  4.4 -  4.4 -
peptides were designed in such a way that they were
variations of an amino acid of the active sequence with
a minimum coupling energy to the receptor, not all
peptides respond in the same manner, as was expected.
Indeed, the SR 116 peptide had already been shown to
have a similar effect as leptin in mice6,7 and in the
current work it shows a similar effect in rats with
increased adiposity due to fat diet. We designed the SH
95 from the sequence of human leptin15 and found that
it also has a similar effect as SR116 in rats. Peptides P80
and P81 are variations of SH95 in amino acid 103 (D/
G) and 95 (G/S)15,16, respectively, and behave similarly.
Note that the change of aspartic for glutamic does not
significantly alter the conformation or the minimum
energy of the P80. The lack of effect of the change of
serine for glutamic in position 95 of P81 is more
difficult to explain, especially when changes in the
same amino acid of the P82 to P84 peptides16 almost
completely diminish the effect.
Weight reduction in animals that were administered
peptides SR116, SH 95, P80, and P81 could be explained
by a possible interaction of the peptides with the
hypothalamic receptor of leptin, which would suppress
appetite. In effect, we found that administering these
peptides diminished the caloric intake of the animals
during the five days of the experiment. It is possible,
then, that processes associated to energy metabolism
are stimulated via the activation of anorexigenic signals
and the inhibition of paths associated to increased
appetite11,22,23.
In addition to appetite reduction, it is possible that
the interaction with the receptor also involves other
signals that increase lipolysis and diminish adiposity;
thus, contributing to diminished body weight4,6,22. In
this study, it is interesting to observe that in the adipose
tissue of animals administered these four peptides there
was significant increase in the production of glycerol
when incubated in preparations free of cells for 90
minutes at 37ºC; this increase was apparently high in
PH 95. These results suggest that in animals treated
with these peptides an action was produced on the lipid
metabolism, probably a lipolysis increase in the
adipocyte that could happen similarly to that reported
with leptin, acting through an autocrine/paracrine action
or through actions controlled by the central nervous
system to stimulate the metabolic routes that generate
faster use of triglyceride deposits and inhibit their
synthesis4,5,24.
Likewise, although we found no DNA fragmentation
in the adipocytes of all the animals that were administered
the peptides, it is clear that all the animals receiving
P80, independent of the dosage administered, showed
DNA fragmentation. For the SR 116, only adipocytes
from one animal and in the SH 95 from four animals
showed DNA fragmentation. Note that for P83 and P84
there was no fragmentation, which would indicate that
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in these animals there was no decrease of adiposity that
would contribute to no weight loss. It is possible that
this is one of the factors that explain why administering
P84 diminishes food intake without weight reduction.
These results suggest the possibility of stimulating
apoptosis processes similar to that observed with
administration of recombinant leptin13,20,21, through
hypothalamic signals associated with the reduction in
NPY levels14, to increased PPARγ expression and
decreased levels of the tumor necrosis factor-alpha, the
latter as a secondary effect to reduced fat mass13.
Similar to the angiopoietin 2 (Ang-2) expression, the
angiogenesis antagonist, promotes apoptosis to increase
the production of the pro-apoptotic BAX proteins and
to increase oxidation of fatty acids in endothelial cells
via activation of the Kinase A protein13,20.
Some studies have shown that one of the leptin
mechanisms to reduce fat deposits is through its ability
to diminish synthesis and secretion of insulin from the
pancreatic b cells and the sensitivity of insulin in
adipose tissue22. We did not find this effect in our
experiments17, which makes it unlikely that the weight
loss found through the administration of SR 116, SH95,
and P80 and P82 involves this mechanism.
As with the study by Grasso et al.6-8 the effect of
weight loss was greater during the first days of peptide
administration and not as the experiment progressed.
Several studies reveal that a high intake of fats,
particularly saturated fats, increases the plasma values
of TChol, LDLc, and TG and decreases those of HDLc25.
Increases in these parameters observed in all the animals
may be due to the diet consumed. However,
administration of recombinant leptin in mice has
demonstrated its potential in diminishing TChol, LDLc,
and TG concentrations and increasing HDL concen-
trations15. Note that administering SH 95 and P80
seems to partially palliate the increase caused by the
diet (Average TChol 90 mg/dl Vs. 106 mg/dl in the rest
of the groups) as done by the recombinant leptin; the
same was found with LDLc. Nevertheless, administering
P80 and P81 increases TGs, contrary to that found with
recombinant leptin. It is possible that these differences
are due to how peptides interact with both hypothalamic
receptors and the very adipocytes.
Peptides SR 116 and SH 95 carried out the same
biological actions. This finding suggests that the SH 95
peptide of the human leptin sequence executes the same
biological functions related to the energetic metabolism
and regulation of body fat in the SR 116 segment.
Comparison of the variables according to the
concentrations under which each peptide was
administered (intra-groups) did not show statistically
significant differences. The results, hence, indicate that
there was no important variation in the effects observed
with the peptides according to the dosage administered,
suggesting a maximum effect in a dosage of 2.5 mg/kg.
In conclusion, the findings suggest that the 95-109
human sequence of the human leptin molecule identified
in the Protein Data Bank as PDB is the human segment
similar to the mouse 116-130 leptin with probable
biological activity to regulate body weight and appetite
and generate lipolysis, as well as possibly apoptosis in
the adipocyte. Likewise, it is insinuated that intra-
peritoneal administering of synthetic peptides in Wistar
rats may execute related actions to body fat control in
an animal model of obesity associated to excessive
intake of fat; specifically, generate diminished appetite,
reduced body weight, increased lipolysis, and possible
apoptosis to reduce fat deposits.
The results also indicate differences in the action
executed by each of the peptides and in the magnitude
of the effect, highlighting the possibility of controlling
the biological response when modifying the structure
of these molecules. Other research is required to
corroborate the effect of the peptides that generated
greater biological response, compare the results with
respect to other treatment alternatives, evaluate their
action over a longer period of time, and identify the
mechanisms through which they execute the action on
the organism.
Conflict of interest. The authors manifest having no
conflicts of interest in the elaboration and execution of
this project.
ACKNOWLEDGMENTS
The authors thank Dr. Carlos Corredor Pereira for
his suggestions and contributions to this publication
and also thank the professionals who participated in
collecting the blood samples and in animal control.
REFERENCES
1. Ceddia RB. Direct metabolic regulation in skeletal muscle and
71
Colombia Médica                         Vol. 42 Nº 1, 2011 (Enero-Marzo)
fat tissue by leptin: implications for glucose and fatty acids
homeostasis. Int J Obes (Lond). 2005; 29: 1175-83.
2. Wang M, Lee Y, Unger R. Novel form of lipolysis induced by
leptin. J Biol Chem. 1999; 25: 17541-4.
3. Zhang H, Kumar S, Bernett A, Eggo M. Intrinsic site-specific
differences in the expression of leptin in human adipocytes
and its autocrine effects on glucose uptake. J Clin Endocrinol.
1999; 7: 2550-5.
4. Rodríguez VM, Macarulla, MT Echevarría, E, Portillo MP.
Lipolysis induced by leptin in rat adipose tissue from different
anatomical locations. Eur J Nutr. 2003; 42: 149-53.
5. Grasso P, Leinung MC, Ingher SP, Lee DW. In vivo effects of
leptin related synthetic peptides on body weight and food
intake in female ob/ob mice. Localization of leptin activity to
domains between amino acid residues 106-140. Endocrinology.
1997; 4: 1413-18.
6. Rozhavskaya A, Lee D, Leinung M, Grasso P. Design of a
synthetic leptin agonist. Effects on energy balance, glucose
homeostasis, and thermoregulation. Endocrinology. 2000; 7:
2501-7.
7. Grasso P, Rozhavskaya-Arena M, Leinung MC, Lee DW. D-
Leu-4- OB3, a synthetic leptin agonist, improves hyperglycemic
control in C57BL/6jJ ob/ob mice. Regul Pept. 2001; 101: 123-
9.
8. Scarpace PJ, Zhang Y. Leptin resistance: a pre-disposing
factor for diet-induced obesity. Am J Physiol Regul Integr
Comp Physiol. 2009; 3: 493-500.
9. Enriori PJ, Evans AE, Sinnayah P, Cowley MA. Leptin
resistance and obesity. Obesity. 2006; 14 (Suppl 5): 254-8.
10. Plantenga M, Saris W, Hukshorn C, Campfield ?. Effects of
weekly administration of pegylated recombinant human OB
protein on appetite profile and energy metabolism. Am J Clin
Nutrition. 2001; 74: 426-34.
11. Kamohara S, Burcelin R, Halaas J, Friedman J, Charron M.
Acute stimulation of glucose metabolism in mice by leptin
treatment. Nature. 1997; 6649: 374-7.
12. Burcelin R, Kamohara S, Li J, Tannenbaum G, Charron M,
Friedman J. Acute intravenous leptin infusion increases glucose
turnover but not skeletal muscle glucose uptake in ob/ob mice.
Diabetes.1999; 48: 1264-9.
13. Gullicksen PS, Asuman DB, Dean RG, Hartzell DL, Baile CA.
Adipose tissue cellularity and apoptosis after intracerebro-
ventricular injections of leptin and 21 days of recovery in rats.
Int J Obesity. 2003; 27: 302-12.
14. Kalaivanisailaja J, Manju V, Nalini N. Lipid profile in mice
fed a high-fat diet after exogenous leptin administration. Pol
J Pharmacol. 2003; 5: 763-9.
15. Poveda E, Lareo L. Diseño teórico de péptidos miméticos de
leptina como farmacóforo para tratamiento de obesidad. Lect
Nutr. 2001; 8: 40-52.
16. Poveda E, Trujillo P, Ruiz F, López E. Glicemia y concentra-
ciones de insulina en sangre de ratas Wistar sometidas a dieta
alta en grasa y a tratamiento con péptidos miméticos de
leptina. Biomedica. 2008; 28: 50-63.
17. Qian H, Azain MJ, Hartzell DL, Baile CA. Increased leptin
resistance as rats grow to maturity. Proc Soc Exp Biol Med.
1998; 2: 160-5.
18. Wang T, Hartzell DL, Rose BS, Flatt WP, Hulsey MG, Menon
NK, et al.  Metabolic responses to intracerebroventricular
leptin and restricted feeding. Physiol Behav. 1999; 4-5: 839-
48.
19. Rodbell M. Metabolism of isolated fat cells. Effects of
hormones on glucose metabolism and lipolysis. J Biol Chem.
1964; 2: 375-80.
20. Della-Fera MA, Choi YH, Hartzell DL, Duan J, Hamrick M,
Baile CA. Sensitivity of ob/ob mice to leptin-induced adipose
tissue apoptosis. Obes Res. 2005; 9: 1540-7.
21. Maedler K, Schulthess FT, Bielman C, Berney T, Bonny C,
Prentki M, et al. Glucose and leptin induce apoptosis in human
beta-cells and impair glucose-stimulated insulin secretion
through activation of c-Jun N-terminal kinases. FASEB J.
2008; 22: 1905-13.
22. Ramsay TG. Porcine leptin inhibits lipogenesis in porcine
adipocytes. J Anim Sci. 2003; 81: 3008-17.
23. Sahu A. Leptin signalling in the hypothalamus: emphasis on
energy homeostasis and leptin resistance. Front Neuro-
endocrinol. 2003; 24: 225-53.
24. Shen J, Tanida M, Mtijima A, Nagaik. In vivo effects of leptin
on autonomic nerve activity and lipolysis in rats. Neurosci
Lett. 2007; 416: 193-7.
25. Denke MA. Dietary fats, fatty acids, and their effects on
lipoproteins. Curr Atheroscler Rep. 2006; 6: 466-71.
